CN100566764C - A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support - Google Patents
A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support Download PDFInfo
- Publication number
- CN100566764C CN100566764C CNB2007101444974A CN200710144497A CN100566764C CN 100566764 C CN100566764 C CN 100566764C CN B2007101444974 A CNB2007101444974 A CN B2007101444974A CN 200710144497 A CN200710144497 A CN 200710144497A CN 100566764 C CN100566764 C CN 100566764C
- Authority
- CN
- China
- Prior art keywords
- medicine coating
- blood vessel
- vessel support
- acid
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000011248 coating agent Substances 0.000 title claims abstract description 80
- 238000000576 coating method Methods 0.000 title claims abstract description 80
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 15
- 238000006068 polycondensation reaction Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 81
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 55
- 229920000305 Nylon 6,10 Polymers 0.000 claims description 29
- 239000004615 ingredient Substances 0.000 claims description 13
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 10
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 10
- 229960002930 sirolimus Drugs 0.000 claims description 10
- 229920002101 Chitin Polymers 0.000 claims description 7
- 229920000954 Polyglycolide Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 239000004633 polyglycolic acid Substances 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 229960004275 glycolic acid Drugs 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 6
- 238000003618 dip coating Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000006731 degradation reaction Methods 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- -1 decanedioic acid glyceryl alcohol ester Chemical class 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support, it has related to the preparation method of a kind of medication coat and drug stent.The medicine coating carrier that the invention solves on the existing coating stent of medicine is easy to generate inflammatory reaction, is easy to generate the problem that degraded comes off in degradation process.The medicine coating carrier that is used for medicine coating blood vessel support of the present invention is prepared by the following method: pre-polymerization, mixing; Promptly obtain medicine coating carrier.Medicine coating blood vessel support of the present invention is prepared according to the following steps: one, pre-polymerization, mixing; Two, polycondensation; Promptly obtain medicine coating blood vessel support.Medicine coating carrier of the present invention has no vitro cytotoxicity, does not produce the advantage of inflammatory reaction, and medicine coating blood vessel support and medicine coating carrier adhesion are strong, the advantage of difficult drop-off in the degradation process.
Description
Technical field
The present invention relates to the preparation method of a kind of medication coat and drug stent.
Background technology
Medicine coating carrier on the coating stent of medicine of exploitation has polylactic acid, polyglycolic acid, poly-propylene oxide and poe etc. now, its major defect medicine coating carrier needs to add extra catalyst and solvent in building-up process, to having a negative impact of biocompatibility, be easy to generate inflammatory reaction, and medicine coating carrier is coated on the support after synthetic, not strong with the support adhesion, discharge in the medicine process in degraded, medication coat is easy to generate large tracts of land and comes off, particularly, bring danger for patient's life as coronary artery stent.
Summary of the invention
The present invention is easy to generate inflammatory reaction for the medicine coating carrier that solves on the existing medicine coating blood vessel support, in degradation process, be easy to generate the problem that degraded comes off, and a kind of preparation method that is used for the medicine coating carrier and the coating stent of medicine of medicine coating blood vessel support is provided.
The medicine coating carrier that is used for medicine coating blood vessel support of the present invention is prepared by the following method: get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously promptly obtains medicine coating carrier; The degraded instrumentality is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan; Wherein ingredient is rapamycin or paclitaxel.
Medicine coating blood vessel support of the present invention is prepared according to the following steps: one, get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously promptly obtains medicine coating carrier; Two, with after the medicine coating carrier dip-coating or spraying to rack surface, polycondensation is 6～8 hours under 120～150 ℃ condition; Promptly obtain medicine coating blood vessel support. Wherein ingredient is rapamycin or paclitaxel.
The ingredient of step 1 was rapamycin or paclitaxel during the medicine coating carrier preparation method that is used for medicine coating blood vessel support of the present invention prepared with medicine coating blood vessel support.
The degraded instrumentality of step 1 is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan in the medicine coating blood vessel support preparation of the present invention; Adding the degraded instrumentality is in order to regulate the mechanical property and the degradation property of synthetic support.
The decanedioic acid in the medicine coating blood vessel support preparation of the present invention in the step 1 and the degree of functionality of glycerol are respectively 2 and 3.
Support in the medicine coating blood vessel support preparation of the present invention in the step 2 is a bare bracket.
Medicine coating blood vessel support of the present invention can be used for the angiostenosis treatment and reduces the restenosis incidence rate.
The medicine coating carrier that is used for medicine coating blood vessel support of the present invention compared with prior art has the following advantages: gather decanedioic acid glyceryl alcohol ester elastomer at no extra catalyst of building-up process and solvent, thereby avoided the negative effect to the material biocompatibility such as extra catalyst and solvent.
Medicine coating blood vessel support of the present invention compared with prior art has the following advantages: (1) carries out polycondensation reaction again because medicine coating blood vessel support of the present invention adopts with the dip-coating of pastille prepolymer or after spraying to rack surface, does not come off so the medicine coating carrier that forms can not produce in degradation process; (2) zoopery shows, poly-decanedioic acid glyceryl alcohol ester elastomer has the favorable tissue reaction, and inflammation and fibrosis are less in the body; There is not tangible swelling phenomenon when (3) degrading; (4) determination of lactate dehydrogenase method and mtt assay are measured no vitro cytotoxicity; (5) degradation process medium-height trestle quality is linear and descends, and its mass loss changes as shown in Figure 1 with degradation time, and the medicine coating carrier that the medicine coating blood vessel support of the present invention's preparation be described is the slow release degraded, does not have the large tracts of land generation that comes off of degrading, and is safe; (6) adhesion of coating and metal rack can reach 3.7～4.5Mpa, and is strong with the support basal body binding force, is suitable for the performance requirement as medicaments coating material, difficult drop-off.
Description of drawings
Fig. 1 is linear change figure for support mass loss of the present invention with degradation time.
The specific embodiment
The specific embodiment one: the medicine coating carrier that is used for medicine coating blood vessel support of present embodiment is prepared by the following method: get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously promptly obtains being used for the medicine coating carrier of medicine coating blood vessel support; The degraded instrumentality is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: get the pre-polymerization 7～9 hours under 140～150 ℃ condition of 0.9～1.1 part of degraded 0.4～0.8 part of instrumentality, 1.4～2 parts of decanedioic acid and glycerol by the mole portion rate.Other step and parameter are identical with the specific embodiment one.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: get the pre-polymerization 8 hours under 145 ℃ condition of 1 part of degraded 0.6 part of instrumentality, 1.7 parts of decanedioic acid and glycerol by the mole portion rate.Other step and parameter are identical with the specific embodiment one.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: ingredient is rapamycin or paclitaxel.Other step and parameter are identical with the specific embodiment one.
The specific embodiment five: present embodiment and the specific embodiment one or fours' difference is: 25%～45% the rapamycin that adds the gross weight of decanedioic acid and glycerol again.Other step and parameter are identical with the specific embodiment one or four.
The specific embodiment six: present embodiment and the specific embodiment one or fours' difference is: 30%～40% the paclitaxel that adds the gross weight of decanedioic acid and glycerol again.Other step and parameter are identical with the specific embodiment one or four.
The specific embodiment seven: present embodiment and the specific embodiment one or fours' difference is: 35% the paclitaxel that adds the gross weight of decanedioic acid and glycerol again.Other step and parameter are identical with the specific embodiment one or four.
The specific embodiment eight: the medicine coating blood vessel support of present embodiment is prepared according to the following steps: one, get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously obtains medicine coating carrier; Two, with after the medicine coating carrier dip-coating or spraying to rack surface, polycondensation is 6～8 hours under 120～150 ℃ condition; Promptly obtain medicine coating blood vessel support; Degraded instrumentality in the step 1 is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment eight is: get the pre-polymerization 7～9 hours under 140～150 ℃ condition of 0.9～1.1 part of degraded 0.4～0.8 part of instrumentality, 1.4～2 parts of decanedioic acid and glycerol by the mole portion rate in the step 1.Other step and parameter are identical with the specific embodiment eight.
The specific embodiment ten: the difference of the present embodiment and the specific embodiment eight is: get the pre-polymerization 8 hours under 145 ℃ condition of 1 part of degraded 0.6 part of instrumentality, 1.7 parts of decanedioic acid and glycerol by the mole portion rate in the step 1.Other step and parameter are identical with the specific embodiment eight.
The specific embodiment 11: the difference of the present embodiment and the specific embodiment eight is: the ingredient in the step 1 in the step 1 is rapamycin or paclitaxel.Other step and parameter are identical with the specific embodiment eight.
The specific embodiment 12: the difference of present embodiment and the specific embodiment eight or 11 is: 25%～45% the rapamycin that adds the gross weight of decanedioic acid and glycerol in the step 1 again.Other step and parameter are identical with the specific embodiment eight or 11.
The specific embodiment 13: the difference of present embodiment and the specific embodiment eight or 11 is: 30%～40% the paclitaxel that adds the gross weight of decanedioic acid and glycerol in the step 1 again.Other step and parameter are identical with the specific embodiment eight or 11.
The specific embodiment 14: the difference of present embodiment and the specific embodiment eight or 11 is: 35% the paclitaxel that adds the gross weight of decanedioic acid and glycerol in the step 1 again.Other step and parameter are identical with the specific embodiment eight or 11.
The specific embodiment 15: the difference of the present embodiment and the specific embodiment eight is: polycondensation 6.5～7.5 hours under 125～145 ℃ condition in the step 2.Other step and parameter are identical with the specific embodiment eight.
The specific embodiment 16: the difference of the present embodiment and the specific embodiment eight is: polycondensation 7 hours under 135 ℃ condition in the step 2.Other step and parameter are identical with the specific embodiment eight.
The specific embodiment 17: the medicine coating blood vessel support of present embodiment is prepared according to the following steps: one, get the pre-polymerization 8 hours under 150 ℃ condition of 1 part of 0.4 part of chitin, 1 part of decanedioic acid and glycerol by the mole portion rate, 30% the rapamycin that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously obtains medicine coating carrier; Two, medicine coating carrier is sprayed to rack surface after, polycondensation is 7 hours under 130 ℃ condition; Promptly obtain medicine coating blood vessel support.
The medicine coating blood vessel support degradation time that present embodiment makes is 60～90 days, support is implanted in the heart coronary artery of pig, support is implanted the no acute complications in back, take out after 30 days, by the face coat micro structure that scanning electron microscope (SEM) is observed support, the no medication coat part that comes off.Take out after 90 days, coating is degraded fully; Detect by the pathology means, no thrombosis forms, the NIP reaction.
Claims (6)
1, a kind of preparation method that is used for the medicine coating carrier of medicine coating blood vessel support, it is characterized in that medicine coating carrier is prepared by the following method: get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously promptly obtains medicine coating carrier; The degraded instrumentality is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan; Wherein ingredient is rapamycin or paclitaxel.
2, a kind of preparation method that is used for the medicine coating carrier of medicine coating blood vessel support according to claim 1 is characterized in that getting the pre-polymerization 7～9 hours under 140～150 ℃ condition of 0.9～1.1 part of degraded 0.4～0.8 part of instrumentality, 1.4～2 parts of decanedioic acid and glycerol by the mole portion rate.
3, a kind of preparation method that is used for the medicine coating carrier of medicine coating blood vessel support according to claim 1 is characterized in that getting the pre-polymerization 8 hours under 145 ℃ condition of 1 part of degraded 0.6 part of instrumentality, 1.7 parts of decanedioic acid and glycerol by the mole portion rate.
4, a kind of preparation method of medicine coating blood vessel support, it is characterized in that medicine coating blood vessel support is prepared according to the following steps: one, get the pre-polymerization 6～10 hours under 130～160 ℃ condition of 0.8～1.2 part of degraded 0.2～1 part of instrumentality, 1～2.5 part of decanedioic acid and glycerol by the mole portion rate, 20%～50% the ingredient that adds the gross weight of decanedioic acid and glycerol again, mix homogeneously obtains medicine coating carrier; Two, with after the medicine coating carrier dip-coating or spraying to rack surface, polycondensation is 6～8 hours under 120～150 ℃ condition, promptly obtains medicine coating blood vessel support; Degraded instrumentality in the step 1 is hydroxyacetic acid, lactic acid, Acetic acid, hydroxy-, bimol. cyclic ester, lactide, chitin, polyglycolic acid, polylactic acid or chitosan; Wherein ingredient is rapamycin or paclitaxel.
5, the preparation method of a kind of medicine coating blood vessel support according to claim 4 is characterized in that in the step 2 under 125～145 ℃ condition polycondensation 6.5～7.5 hours.
6, the preparation method of a kind of medicine coating blood vessel support according to claim 4 is characterized in that in the step 2 under 135 ℃ condition polycondensation 7 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007101444974A CN100566764C (en) | 2007-10-26 | 2007-10-26 | A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007101444974A CN100566764C (en) | 2007-10-26 | 2007-10-26 | A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101147813A CN101147813A (en) | 2008-03-26 |
| CN100566764C true CN100566764C (en) | 2009-12-09 |
Family
ID=39248583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007101444974A Expired - Fee Related CN100566764C (en) | 2007-10-26 | 2007-10-26 | A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100566764C (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013170052A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
| EP2796591B1 (en) | 2009-05-13 | 2016-07-06 | SiO2 Medical Products, Inc. | Apparatus and process for interior coating of vessels |
| US7985188B2 (en) | 2009-05-13 | 2011-07-26 | Cv Holdings Llc | Vessel, coating, inspection and processing apparatus |
| US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
| US11624115B2 (en) | 2010-05-12 | 2023-04-11 | Sio2 Medical Products, Inc. | Syringe with PECVD lubrication |
| US9878101B2 (en) | 2010-11-12 | 2018-01-30 | Sio2 Medical Products, Inc. | Cyclic olefin polymer vessels and vessel coating methods |
| US9272095B2 (en) | 2011-04-01 | 2016-03-01 | Sio2 Medical Products, Inc. | Vessels, contact surfaces, and coating and inspection apparatus and methods |
| DE102011107109A1 (en) * | 2011-07-12 | 2013-01-17 | Translumina Gmbh | Implantable vascular support |
| US11116695B2 (en) | 2011-11-11 | 2021-09-14 | Sio2 Medical Products, Inc. | Blood sample collection tube |
| WO2013071138A1 (en) | 2011-11-11 | 2013-05-16 | Sio2 Medical Products, Inc. | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS |
| CN104854257B (en) | 2012-11-01 | 2018-04-13 | Sio2医药产品公司 | coating inspection method |
| WO2014078666A1 (en) | 2012-11-16 | 2014-05-22 | Sio2 Medical Products, Inc. | Method and apparatus for detecting rapid barrier coating integrity characteristics |
| CN105705676B (en) | 2012-11-30 | 2018-09-07 | Sio2医药产品公司 | Control the uniformity of the PECVD depositions on injector for medical purpose, cylindrantherae etc. |
| US9764093B2 (en) | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
| US9662450B2 (en) | 2013-03-01 | 2017-05-30 | Sio2 Medical Products, Inc. | Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
| US9937099B2 (en) | 2013-03-11 | 2018-04-10 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
| KR102472240B1 (en) | 2013-03-11 | 2022-11-30 | 에스아이오2 메디컬 프로덕츠, 인크. | Coated Packaging |
| EP2971227B1 (en) | 2013-03-15 | 2017-11-15 | Si02 Medical Products, Inc. | Coating method. |
| WO2015148471A1 (en) | 2014-03-28 | 2015-10-01 | Sio2 Medical Products, Inc. | Antistatic coatings for plastic vessels |
| CN104147606B (en) * | 2014-08-15 | 2016-03-16 | 吕鹏威 | For the biodegradation subdermal implantation rod of long-acting blood pressure lowering |
| CN116982977A (en) | 2015-08-18 | 2023-11-03 | Sio2医药产品公司 | Medicaments and other packages with low oxygen transmission rate |
| EP3427763B1 (en) | 2016-03-10 | 2022-08-10 | Shandong Rientech Medical Tech Co., Ltd. | Degradable zinc base alloy implant material and preparation method and use thereof |
-
2007
- 2007-10-26 CN CNB2007101444974A patent/CN100566764C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 冠脉支架表面载药涂层的制备和性能. 谭丽丽等.材料研究学报，第18卷第4期. 2004 |
| 冠脉支架表面载药涂层的制备和性能. 谭丽丽等.材料研究学报，第18卷第4期. 2004 * |
| 可生物降解聚癸二酸丙三醇酯弹性体的制备及表征. 刘全勇等.合成橡胶工业，第29卷第1期. 2006 |
| 可生物降解聚癸二酸丙三醇酯弹性体的制备及表征. 刘全勇等.合成橡胶工业，第29卷第1期. 2006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101147813A (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100566764C (en) | A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support | |
| US8021678B2 (en) | Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics | |
| WO2015062547A1 (en) | Bioresorbable iron-based alloy stent | |
| US20120231165A1 (en) | Application of Supercritical Fluid Technology for Manufacturing Soft Tissue Repair Medical Articles | |
| JP2009525812A5 (en) | ||
| EP3366325B1 (en) | Absorbable iron-based alloy implantable medical device | |
| WO2007092583A2 (en) | Functionalizing implantable devices with a poly (diol-co-citrate) polymer | |
| WO2012100651A1 (en) | Biodegradable stent formed with polymer-bioceramic nanoparticle composite and preparation method thereof | |
| CN106310372B (en) | Degradable magnesium-based intrabony implant drug-loaded polymer/calcium-phosphorus composite coating and preparation | |
| EP3381415B1 (en) | Bioabsorbable stent | |
| CN101869723A (en) | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method | |
| CN109939271B (en) | Coating structure of medical biodegradable zinc alloy stent and preparation method thereof | |
| CN112472879A (en) | Magnesium alloy stent and preparation method thereof | |
| CN108324998B (en) | Preparation method of polyurethane multichannel intravascular stent and coating liquid used by same | |
| CN110075369A (en) | Metal-macromolecule compound rest and its preparation method and application of degradation rate is adjusted with Multi-layer design | |
| CN108079386B (en) | Bacterial cellulose composite forming material and preparation method thereof | |
| WO2016107366A1 (en) | Degradable iron-base alloy support | |
| CN104107459A (en) | Degradable polymer coating support with sequential response function, and making method thereof | |
| RU2571685C2 (en) | Implanted stent | |
| CN106668952B (en) | Multi-coating biodegradable metal stent and preparation method thereof | |
| US9314550B2 (en) | Implant matrix made of a polymer mixture | |
| CN109172075A (en) | A kind of degradable intravascular stent and preparation method thereof containing elastic layer | |
| CN202740163U (en) | Cardiovascular medicament coating rack | |
| Wang et al. | Poly (glycerol sebacate) in tissue engineering and regenerative medicine | |
| CN105797207A (en) | Drug release carrier on metal substrate and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091209 |